Comparison of Conditioning with Fludarabine/Busulfan and Fludarabine/Melphalan in Allogeneic Transplantation Recipients 50 Years or Older Koji Kawamura,

Slides:

Advertisements

Similar presentations

Allogeneic stem cell transplantation for adult Philadelphia chromosome–negative acute lymphocytic leukemia: comparable survival rates but different risk.

Advertisements

Mismatch on Glutathione S-Transferase T1 Increases the Risk of Graft-versus-Host Disease and Mortality after Allogeneic Stem Cell Transplantation María.

Changes in the Clinical Impact of High-Risk Human Leukocyte Antigen Allele Mismatch Combinations on the Outcome of Unrelated Bone Marrow Transplantation

Comparison of Allogeneic Hematopoietic Cell Transplantation and Chemotherapy in Elderly Patients with Non-M3 Acute Myelogenous Leukemia in First Complete.

Efficacy and Long-Term Outcome of Treatment for Pure Red Cell Aplasia after Allogeneic Stem Cell Transplantation from Major ABO-Incompatible Donors Makoto.

Graft-Versus-Host Disease and Survival after Cord Blood Transplantation for Acute Leukemia: A Comparison of Japanese versus White Populations Yachiyo.

Influence of Differently Licensed KIR2DL1-Positive Natural Killer Cells in Transplant Recipients with Acute Leukemia: A Japanese National Registry Study

Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia Scott R. Solomon, Connie A. Sizemore, Xu Zhang,

Allogeneic Hematopoietic Stem Cell Transplantation for Adolescents and Young Adults with Acute Myeloid Leukemia Daisuke Tomizawa, Shiro Tanaka, Tadakazu.

Haploidentical and Matched Sibling Donor Hematopoietic Cell Transplantation for Patients with HLA-Homozygous Haplotypes Junya Kanda, Kazuhiro Ikegame,

Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years Cynthia Huisman,

Outcome of Second Transplantation Using Umbilical Cord Blood for Graft Failure after Allogeneic Hematopoietic Stem Cell Transplantation for Aplastic Anemia

Impact of Race on Graft-Versus-Host Disease Rates after HLA-Matched Sibling Bone Marrow or Peripheral Blood Hematopoietic Cell Transplantation: Comparison.

Sabina Kersting, Leo F. Verdonck

Chronic Kidney Disease in Long-Term Survivors after Allogeneic Hematopoietic Stem Cell Transplantation: Retrospective Analysis at a Single Institute

Betty T. Tran, Abigail Halperin, Jason W. Chien

Comparison of Different Rabbit Anti-Thymocyte Globulin Formulations in Allogeneic Stem Cell Transplantation: Systematic Literature Review and Network.

Cord Blood Transplantation for Multiple Myeloma: A Study from the Multiple Myeloma Working Group of the Japan Society for Hematopoietic Cell Transplantation

Comparison of Cord Blood Transplantation with Unrelated Bone Marrow Transplantation in Patients Older than Fifty Years Masatsugu Tanaka, Koichi Miyamura,

Donor-to-Recipient ABO Mismatch Does Not Impact Outcomes of Allogeneic Hematopoietic Cell Transplantation Regardless of Graft Source Sharat Damodar,

Comparison of Autologous and Unrelated Transplants for Cytogenetically Normal Acute Myelogenous Leukemia Motonori Mizutani, Akiyoshi Takami, Masahiko.

Fludarabine-Melphalan Conditioning for AML and MDS: Alemtuzumab Reduces Acute and Chronic GVHD without Affecting Long-Term Outcomes Koen Van Besien,

Cytomegalovirus Infection after Allogeneic Transplantation: Comparison of Cord Blood with Peripheral Blood and Marrow Graft Sources Christopher M. Walker,

Low Relapse without Excessive Transplant-Related Mortality following Myeloablative Cord Blood Transplantation for Acute Leukemia in Complete Remission:

Allogeneic Bone Marrow Transplantation from Unrelated Human T-Cell Leukemia Virus- I–negative Donors for Adult T-Cell Leukemia/Lymphoma: Retrospective.

Total Marrow Lymphoid Irradiation/Fludarabine/ Melphalan Conditioning for Allogeneic Hematopoietic Cell Transplantation Lindsay G. Jensen, Tracey Stiller,

Nonmyeloablative Unrelated Donor Hematopoietic Cell Transplantation to Treat Patients with Poor-Risk, Relapsed, or Refractory Multiple Myeloma George.

Quality of Life after Allogeneic Hematopoietic Cell Transplantation According to Affected Organ and Severity of Chronic Graft-versus-Host Disease Saiko.

Donor Lymphocyte Infusion for the Treatment of Relapsed Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective.

Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation.

Single Cord Blood Combined with HLA-Mismatched Third Party Donor Cells: Comparable Results to Matched Unrelated Donor Transplantation in High-Risk Patients.

Low Risk of Chronic Graft-versus-Host Disease and Relapse Associated with T Cell– Depleted Peripheral Blood Stem Cell Transplantation for Acute Myelogenous.

Reducing Treatment-Related Mortality Did Not Improve Outcomes of Allogeneic Myeloablative Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma:

Total Body Irradiation–Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation.

Preengraftment Serum C-Reactive Protein (CRP) Value May Predict Acute Graft-versus- Host Disease and Nonrelapse Mortality after Allogeneic Hematopoietic.

Recipient PTPN22 −1123 C/C Genotype Predicts Acute Graft-versus-Host Disease after HLA Fully Matched Unrelated Bone Marrow Transplantation for Hematologic.

Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck

Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and Mini-Methotrexate (Tac/Sir/MTX) as Acute Graft-versus-Host Disease.

A Comparison of Outcomes for Cord Blood Transplantation and Unrelated Bone Marrow Transplantation in Adult Aplastic Anemia Yachiyo Kuwatsuka, Junya Kanda,

Impact of Donor and Recipient Sex and Parity on Outcomes of HLA-Identical Sibling Allogeneic Hematopoietic Stem Cell Transplantation Alison W. Loren,

Graft-versus-Host Disease after HLA-Matched Sibling Bone Marrow or Peripheral Blood Stem Cell Transplantation: Comparison of North American Caucasian.

Analysis of Risk Factors for Hepatic Acute Graft-Versus-Host Disease By Using Transplant Registry Data in Japan Yasuyuki Arai, MD, Junya Kanda, MD, Hideki.

Improved Nonrelapse Mortality and Infection Rate with Lower Dose of Antithymocyte Globulin in Patients Undergoing Reduced-Intensity Conditioning Allogeneic.

Myeloablative Transplantation using either Cord Blood or Bone Marrow leads to Immune Recovery, High Long-Term Donor Chimerism and Excellent Survival in.

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Myelodysplastic Syndrome Harboring Trisomy 8 Takaaki Konuma, Yasushi.

Late Mortality and Causes of Death among Long-Term Survivors after Allogeneic Stem Cell Transplantation Yoshiko Atsuta, Akihiro Hirakawa, Hideki Nakasone,

Kinetics and Risk Factors of Relapse after Allogeneic Stem Cell Transplantation in Children with Leukemia: A Long-Term Follow-Up Single-Center Study

Impact of Graft-versus-Host Disease on Allogeneic Hematopoietic Cell Transplantation for Adult T Cell Leukemia-Lymphoma Focusing on Preconditioning Regimens:

Risk Stratification of Outcomes Among Patients with Adult T-Cell Leukemia/Lymphoma Receiving Allogeneic Hematopoietic Cell Transplantation: A Retrospective.

Comparison of Graft-Versus-Host Disease-Free, Relapse-Free Survival (GRFS) of Patients with Hematological Malignancy According to Donor Type: JSHCT Working.

Double Umbilical Cord Blood Transplantation after Novel Myeloablative Conditioning Using a Regimen of Fludarabine, Busulfan, and Total Lymphoid Irradiation

Comparison of Outcomes for Pediatric Patients With Acute Myeloid Leukemia in Remission and Undergoing Allogeneic Hematopoietic Cell Transplantation With.

Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia Patients with Central Nervous System Involvement Jun Aoki, Ken.

Outcomes of Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients with Abnormalities of the Short Arm of Chromosome 17 Jinichi.

Reduced-Intensity Allogeneic Transplant in Patients Older Than 55 Years: Unrelated Umbilical Cord Blood Is Safe and Effective for Patients without a Matched.

Impacts of thymoglobulin in patients with acute leukemia in remission undergoing allogeneic HSCT from different donors by Manabu Wakamatsu, Seitaro Terakura,

Double-Unit Cord Blood Transplantation after Myeloablative Conditioning for Patients with Hematologic Malignancies: A Multicenter Phase II Study in Japan

Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and.

Blood and Marrow Transplant Handbook

Impact of the Direction of HLA Mismatch on Transplantation Outcomes in Single Unrelated Cord Blood Transplantation Junya Kanda, Yoshiko Atsuta, Atsushi.

IFN-α Is Effective for Treatment of Minimal Residual Disease in Patients with Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation:

Treosulfan, Fludarabine, and 2-Gy Total Body Irradiation Followed by Allogeneic Hematopoietic Cell Transplantation in Patients with Myelodysplastic Syndrome.

Homozygous HLA-C1 is Associated with Reduced Risk of Relapse after HLA-Matched Transplantation in Patients with Myeloid Leukemia Nobuyoshi Arima, Junya.

Low Serum Levels of Total Rabbit-IgG Is Associated with Acute Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation:

Extramedullary Relapse of Acute Myelogenous Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Better Prognosis Than Systemic Relapse

Prospective Multicenter Study of Single-Unit Cord Blood Transplantation with Myeloablative Conditioning for Adult Patients with High-Risk Hematologic.

High probability of follow-up termination among AYA survivors after allogeneic hematopoietic cell transplantation by Koichi Miyamura, Takuya Yamashita,

Impact of Human Leukocyte Antigen Allele Mismatch in Unrelated Bone Marrow Transplantation with Reduced-Intensity Conditioning Regimen Hisayuki Yokoyama,

Cannabidiol for the Prevention of Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation: Results of a Phase II Study Moshe Yeshurun,

Presentation transcript:

Comparison of Conditioning with Fludarabine/Busulfan and Fludarabine/Melphalan in Allogeneic Transplantation Recipients 50 Years or Older Koji Kawamura, Shinichi Kako, Shuichi Mizuta, Ken Ishiyama, Jun Aoki, Shingo Yano, Takahiro Fukuda, Naoyuki Uchida, Yukiyasu Ozawa, Tetsuya Eto, Koji Iwato, Heiwa Kanamori, Kaoru Kahata, Tadakazu Kondo, Masashi Sawa, Tatsuo Ichinohe, Yoshiko Atsuta, Yoshinobu Kanda Biology of Blood and Marrow Transplantation Volume 23, Issue 12, Pages 2079-2087 (December 2017) DOI: 10.1016/j.bbmt.2017.09.003 Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 OS (A, standard risk; B, high risk), DFS (C, standard risk; D, high risk), relapse (E), and NRM (F) in the FB2, FB4, and FM140 groups. Biology of Blood and Marrow Transplantation 2017 23, 2079-2087DOI: (10.1016/j.bbmt.2017.09.003) Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Cumulative incidences of grades II to IV (A) and III to IV (B) acute GVHD and chronic (C) and extensive chronic (D) GVHD in the FB2, FB4, and FM140 groups. Biology of Blood and Marrow Transplantation 2017 23, 2079-2087DOI: (10.1016/j.bbmt.2017.09.003) Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 OS (A, standard-risk AML; B, high-risk AML; C, standard-risk ALL; D, high-risk ALL; E, standard-risk MDS; F, high-risk MDS) in the FB2, FB4, and FM140 groups, classified according to the background disease. Biology of Blood and Marrow Transplantation 2017 23, 2079-2087DOI: (10.1016/j.bbmt.2017.09.003) Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 4 Cumulative incidence of relapse (A, AML; C, ALL; E, MDS) and NRM (B, AML; D, ALL; F, MDS) in the FB2, FB4, and FM140 groups, classified according to the background disease. Biology of Blood and Marrow Transplantation 2017 23, 2079-2087DOI: (10.1016/j.bbmt.2017.09.003) Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions